Cotellic

cobimetinib · Roche Registration GmbH
AUTHORISED IN THE EU

What Cotellic is used for

Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Cotellic
Active substance
cobimetinib
Disease area
Melanoma
Medicine group
Antineoplastic agents
ATC code
L01XE38
Marketing authorisation holder
Roche Registration GmbH
Authorised in the EU since
2015

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Cotellic used for?

Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

What is the active substance in Cotellic?

Cotellic contains cobimetinib.

Who makes Cotellic?

The EU marketing authorisation holder is Roche Registration GmbH.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.